Medibio Limited
(ASX:MEB) says its new research study has marked a scientific breakthrough in the objective diagnosis of post traumatic stress disorder (PTSD).
The medical technology company says its study at the Emory University in Atlana found that PTSD can be accurately diagnosed via a non-invasive tool, using heart rate data and machine learning algorithms.
Medibio funded and licensed the study, while it also holds the exclusive rights to commercialise the technology.
The company says its technology will assist in screening, diagnosing and treating mental illness among military service personnel.
Shares in Medibio Limited
(ASX:MEB) are trading 7.69 per cent higher to 35 cents.
